Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Isabel Arrillaga-Romany, M.D.

Co-Author

This page shows the publications co-authored by Isabel Arrillaga-Romany and Tracy Batchelor.
Connection Strength

3.251
  1. Performance of a Hospital Pathway for Patients With a New Single Brain Mass. J Oncol Pract. 2019 Mar; 15(3):e211-e218.
    View in: PubMed
    Score: 0.827
  2. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 May 12.
    View in: PubMed
    Score: 0.734
  3. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 Oct 03; 8(45):79298-79304.
    View in: PubMed
    Score: 0.734
  4. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.227
  5. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020 01 11; 22(1):94-102.
    View in: PubMed
    Score: 0.221
  6. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
    View in: PubMed
    Score: 0.196
  7. MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab060.
    View in: PubMed
    Score: 0.060
  8. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019 05 06; 21(5):669-677.
    View in: PubMed
    Score: 0.053
  9. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221.
    View in: PubMed
    Score: 0.052
  10. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313.
    View in: PubMed
    Score: 0.051
  11. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
    View in: PubMed
    Score: 0.050
  12. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract. 2018 Mar; 5(1):64-68.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.